DK2266603T3 - Tumorvacciner - Google Patents

Tumorvacciner

Info

Publication number: DK2266603T3
Authority: DK; Denmark
Prior art keywords: ascl; hash; tumor vaccines; monophosphoryl lipid; lipid
Prior art date: 2000-10-18

Application number

DK10170408.8T

Other languages

English (en)

Inventor

Nathalie Garcon

Catherine Marie Ghislaine Gerard

Jean Stephenne

Original Assignee

Glaxosmithkline Biolog Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-18

Filing date

2001-10-16

Publication date

2012-11-05

2000-10-18 Priority claimed from GB0025573A external-priority patent/GB0025573D0/en

2000-10-18 Priority claimed from US09/690,921 external-priority patent/US6544518B1/en

2000-10-18 Priority claimed from GB0025574A external-priority patent/GB0025574D0/en

2001-10-16 Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa

2001-10-16 Priority claimed from EP07121675A external-priority patent/EP1889630B1/en

2012-11-05 Application granted granted Critical

2012-11-05 Publication of DK2266603T3 publication Critical patent/DK2266603T3/da

Links

206010028980 Neoplasm Diseases 0.000 title abstract 3
229960005486 vaccine Drugs 0.000 title 1
239000002671 adjuvant Substances 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
229940035032 monophosphoryl lipid a Drugs 0.000 abstract 2
102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
101710188053 Protein D Proteins 0.000 abstract 1
101710132893 Resolvase Proteins 0.000 abstract 1
239000002158 endotoxin Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
108020001507 fusion proteins Proteins 0.000 abstract 1
102000037865 fusion proteins Human genes 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
229920006008 lipopolysaccharide Polymers 0.000 abstract 1
238000012737 microarray-based gene expression Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000012243 multiplex automated genomic engineering Methods 0.000 abstract 1
239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
229930182490 saponin Natural products 0.000 abstract 1
150000007949 saponins Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Permanent Magnet Type Synchronous Machine (AREA)
Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK10170408.8T 2000-10-18 2001-10-16 Tumorvacciner DK2266603T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0025573A GB0025573D0 (en)	2000-10-18	2000-10-18	Vaccine
US09/690,921 US6544518B1 (en)	1999-04-19	2000-10-18	Vaccines
GB0025574A GB0025574D0 (en)	2000-10-18	2000-10-18	Vaccine
EP07121675A EP1889630B1 (en)	2000-10-18	2001-10-16	Vaccines comprising MAGE antigen linked to protein D fragment

Publications (1)

Publication Number	Publication Date
DK2266603T3 true DK2266603T3 (da)	2012-11-05

Family

ID=34082077

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK10170408.8T DK2266603T3 (da)	2000-10-18	2001-10-16	Tumorvacciner
DK07121675.8T DK1889630T3 (da)	2000-10-18	2001-10-16	Vacciner omfattende MAGE-antigen koblet til protein D-fragment

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK07121675.8T DK1889630T3 (da)	2000-10-18	2001-10-16	Vacciner omfattende MAGE-antigen koblet til protein D-fragment

Country Status (14)

Country	Link
US (1)	US20050019340A1 (da)
EP (1)	EP2266603B1 (da)
JP (1)	JP2008285487A (da)
KR (1)	KR100831139B1 (da)
AT (1)	ATE534401T1 (da)
CY (3)	CY1108526T1 (da)
DE (1)	DE60131670T2 (da)
DK (2)	DK2266603T3 (da)
ES (2)	ES2392943T3 (da)
HK (3)	HK1057992A1 (da)
IL (1)	IL155282A (da)
PL (1)	PL211151B1 (da)
PT (3)	PT1326638E (da)
SI (1)	SI2266603T1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US8574599B1 (en)	1998-05-22	2013-11-05	Ottawa Hospital Research Institute	Methods and products for inducing mucosal immunity
US7807803B2 (en) *	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) *	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) *	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
WO2004053104A2 (en) *	2002-12-11	2004-06-24	Coley Pharmaceutical Group, Inc.	5’ cpg nucleic acids and methods of use
EP1608403A2 (en) *	2003-04-02	2005-12-28	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP1623715B1 (en) *	2004-07-13	2012-09-19	Charité - Universitätsmedizin Berlin	A composition comprising a pharmacologically active agent coupled to a target cell specific component, and a saponin

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3238190A (en)	1963-10-23	1966-03-01	Madaus & Co K G Fa Dr	Aescin recovery
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
SE8205892D0 (sv) *	1982-10-18	1982-10-18	Bror Morein	Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US4806350A (en) *	1986-04-18	1989-02-21	Norden Laboratories, Inc.	Vaccine formulation
US6054438A (en)	1987-01-07	2000-04-25	Imperial Cancer Research Technology Limited	Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
CA1339204C (en)	1987-01-07	1997-08-05	Joyce Taylor-Papadimitriou	Mucin core polypeptide, antibodies and probes
CA1331443C (en)	1987-05-29	1994-08-16	Charlotte A. Kensil	Saponin adjuvant
US5057540A (en) *	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US4963484A (en)	1988-01-29	1990-10-16	Dana-Farber Cancer Institute, Inc.	Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
ATE115862T1 (de)	1989-02-04	1995-01-15	Akzo Nobel Nv	Tocole als impfstoffadjuvans.
HU212924B (en)	1989-05-25	1996-12-30	Chiron Corp	Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr)	1989-07-03	1991-10-25	Seppic Sa	Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr)	1989-07-03	1991-10-25	Seppic Sa	Emulsions multiphasiques injectables
US5256643A (en)	1990-05-29	1993-10-26	The Government Of The United States	Human cripto protein
SE466259B (sv)	1990-05-31	1992-01-20	Arne Forsgren	Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
JP3723231B2 (ja)	1991-12-23	2005-12-07	ディミナコアクチェンゲゼルシャフト	アジュバント
KR100278157B1 (ko)	1992-06-25	2001-01-15	장 스테판느	보조약을 함유하는 백신 조성물
US5786148A (en)	1996-11-05	1998-07-28	Incyte Pharmaceuticals, Inc.	Polynucleotides encoding a novel prostate-specific kallikrein
US5801005A (en)	1993-03-17	1998-09-01	University Of Washington	Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
DE69428136T3 (de)	1993-03-23	2008-07-10	Smithkline Beecham Biologicals S.A.	3-0-Deazylierte Monophosphoryl Lipid A enthaltende Impfstoff-Zusammensetzungen
US5744144A (en)	1993-07-30	1998-04-28	University Of Pittsburgh University Patent Committee Policy And Procedures	Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
PT729473E (pt)	1993-11-17	2001-02-28	Deutsche Om Arzneimittel Gmbh	Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US5688506A (en)	1994-01-27	1997-11-18	Aphton Corp.	Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
JP3468773B2 (ja)	1994-07-15	2003-11-17	ザユニバーシティオブアイオワリサーチファウンデーション	免疫調節オリゴヌクレオチド
AUPM873294A0 (en)	1994-10-12	1994-11-03	Csl Limited	Saponin preparations and use thereof in iscoms
UA56132C2 (uk) *	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en)	1996-10-05	1996-11-20	Smithkline Beecham Plc	Vaccines
US5668267A (en)	1995-05-31	1997-09-16	Washington University	Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
US5981215A (en)	1995-06-06	1999-11-09	Human Genome Sciences, Inc.	Human criptin growth factor
US5666153A (en)	1995-10-03	1997-09-09	Virtual Shopping, Inc.	Retractable teleconferencing apparatus
AU3399197A (en)	1996-06-18	1998-01-07	Alza Corporation	Device for enhancing transdermal agent delivery or sampling
DK0909562T3 (da)	1996-07-03	2005-08-22	Eisai Co Ltd	Injektionspræparat indeholdende en lipid A analog og fremgangsmåde til fremstilling deraf
US5955306A (en)	1996-09-17	1999-09-21	Millenium Pharmaceuticals, Inc.	Genes encoding proteins that interact with the tub protein
EP0930893B1 (en)	1996-10-11	2005-04-13	The Regents of The University of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
US6231859B1 (en) *	1996-12-02	2001-05-15	Aquila Biopharmaceuticals, Inc.	Saponin adjuvant compositions
KR100453132B1 (ko)	1996-12-20	2004-10-15	앨자 코포레이션	경피 약제 플럭스를 향상시키기 위한 장치 및 방법
US5840871A (en)	1997-01-29	1998-11-24	Incyte Pharmaceuticals, Inc.	Prostate-associated kallikrein
US6887660B2 (en)	1997-02-25	2005-05-03	Corixa Corporation	Compounds for immunodiagnosis of prostate cancer and methods for their use
JP3036686B2 (ja)	1997-02-27	2000-04-24	政夫高橋	冠状動脈のバイパス手術に用いる血管吻合部の止血保持装置
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
HUP0001403A3 (en)	1997-04-01	2003-05-28	Corixa Corp Seattle	Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
ZA982968B (en)	1997-04-09	1998-10-27	Corixa Corp	Compositions and methods for the treatment and diagnosis of breast cancer
US6130043A (en)	1997-05-02	2000-10-10	Abbott Laboratories	Reagents and methods useful for detecting diseases of the prostate
US5993412A (en)	1997-05-19	1999-11-30	Bioject, Inc.	Injection apparatus
GB9711990D0 (en)	1997-06-11	1997-08-06	Smithkline Beecham Biolog	Vaccine
EP0988053A1 (en)	1997-06-11	2000-03-29	Aquila Biopharmaceuticals, Inc.	Purified saponins as oral adjuvants
EP2050465B1 (en)	1997-08-29	2014-06-11	Antigenics Inc.	Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient
GB9718901D0 (en)	1997-09-05	1997-11-12	Smithkline Beecham Biolog	Vaccine
EP1279401B1 (en)	1997-09-05	2008-01-09	GlaxoSmithKline Biologicals S.A.	Oil in water emulsions containing saponins
WO1999019479A1 (en)	1997-09-26	1999-04-22	Corixa Corporation	Murine model for human carcinoma
AU756828B2 (en)	1997-12-02	2003-01-23	Powderject Vaccines, Inc.	Transdermal delivery of particulate vaccine compositions
CA2316397A1 (en)	1997-12-24	1999-07-08	Corixa Corporation	Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
NZ506086A (en)	1998-02-05	2003-01-31	Smithkline Beecham Biolog S	Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins, antigens comprising derivatised thiol residues and of compositions for vaccination
JP2002511266A (ja)	1998-04-15	2002-04-16	ルードヴィッヒインスティテュートフォーキャンサーリサーチ	腫瘍関連核酸及びその使用
US8574599B1 (en) *	1998-05-22	2013-11-05	Ottawa Hospital Research Institute	Methods and products for inducing mucosal immunity
EP1870466A3 (en)	1998-07-14	2008-03-19	Corixa Corporation	Compositions and methods for therapy and diagnosis of prostate cancer
AU773204C (en) *	1998-08-10	2005-05-19	Antigenics Llc	Compositions of CPG and saponin adjuvants and methods thereof
CN1133568C (zh)	1999-01-18	2004-01-07	地球制药株式会社	气溶胶扩散喷雾器
CA2361009C (en)	1999-01-29	2012-10-23	Corixa Corporation	Her-2/neu fusion proteins
AU3391200A (en)	1999-03-04	2000-09-21	Corixa Corporation	Compositions and methods for breast cancer therapy and diagnosis
GB9905124D0 (en) *	1999-03-05	1999-04-28	Smithkline Beecham Biolog	Novel compounds
EP1187629B1 (en) *	1999-04-19	2004-09-22	GlaxoSmithKline Biologicals S.A.	Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6558670B1 (en) *	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
WO2001002828A2 (en) *	1999-07-07	2001-01-11	Tularik Inc.	Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
KR20090085697A (ko) *	2000-02-23	2009-08-07	글락소스미스클라인 바이오로지칼즈 에스.에이.	종양 특이적 동물 단백질
AU2010252012A1 (en) *	2009-05-27	2011-12-22	Glaxosmithkline Biologicals S.A.	CASB7439 constructs

2001
- 2001-10-16 DK DK10170408.8T patent/DK2266603T3/da active
- 2001-10-16 KR KR1020037005465A patent/KR100831139B1/ko not_active IP Right Cessation
- 2001-10-16 EP EP10170408A patent/EP2266603B1/en not_active Expired - Lifetime
- 2001-10-16 DK DK07121675.8T patent/DK1889630T3/da active
- 2001-10-16 PT PT01987671T patent/PT1326638E/pt unknown
- 2001-10-16 US US10/478,188 patent/US20050019340A1/en not_active Abandoned
- 2001-10-16 PL PL391896A patent/PL211151B1/pl unknown
- 2001-10-16 DE DE60131670T patent/DE60131670T2/de not_active Expired - Lifetime
- 2001-10-16 ES ES10170408T patent/ES2392943T3/es not_active Expired - Lifetime
- 2001-10-16 ES ES07121675T patent/ES2377077T3/es not_active Expired - Lifetime
- 2001-10-16 AT AT07121675T patent/ATE534401T1/de active
- 2001-10-16 PT PT10170408T patent/PT2266603E/pt unknown
- 2001-10-16 PT PT07121675T patent/PT1889630E/pt unknown
- 2001-10-16 SI SI200131015T patent/SI2266603T1/sl unknown
2003
- 2003-04-08 IL IL155282A patent/IL155282A/en not_active IP Right Cessation
- 2003-12-08 HK HK03108907A patent/HK1057992A1/xx not_active IP Right Cessation
2008
- 2008-01-31 CY CY20081100112T patent/CY1108526T1/el unknown
- 2008-04-10 HK HK08104079.8A patent/HK1117729A1/xx not_active IP Right Cessation
- 2008-04-10 HK HK11100837.4A patent/HK1147673A1/xx not_active IP Right Cessation
- 2008-05-14 JP JP2008126888A patent/JP2008285487A/ja active Pending
2012
- 2012-02-14 CY CY20121100147T patent/CY1112658T1/el unknown
- 2012-10-26 CY CY20121101024T patent/CY1113735T1/el unknown

Also Published As

Publication number	Publication date
HK1057992A1 (en)	2004-04-30
CY1108526T1 (el)	2014-04-09
DE60131670T2 (de)	2008-10-30
SI2266603T1 (sl)	2012-12-31
EP2266603B1 (en)	2012-09-12
JP2008285487A (ja)	2008-11-27
PT1326638E (pt)	2008-02-06
KR100831139B1 (ko)	2008-05-20
HK1147673A1 (en)	2011-08-19
EP2266603A1 (en)	2010-12-29
IL155282A (en)	2010-11-30
ATE534401T1 (de)	2011-12-15
PT1889630E (pt)	2012-02-29
ES2377077T3 (es)	2012-03-22
KR20030044015A (ko)	2003-06-02
PL211151B1 (pl)	2012-04-30
CY1113735T1 (el)	2016-06-22
PT2266603E (pt)	2012-11-02
ES2392943T3 (es)	2012-12-17
US20050019340A1 (en)	2005-01-27
DE60131670D1 (de)	2008-01-10
DK1889630T3 (da)	2012-03-05
HK1117729A1 (en)	2009-01-23
CY1112658T1 (el)	2016-02-10

Publication	Publication Date	Title
HK1147673A1 (en)	2011-08-19	Tumour vaccines
PT1104306E (pt)	2006-05-31	Composicoes de cpg e adjuvantes de saponina e seus metodos
BR0114786A (pt)	2003-08-12	Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
IS4518A (is)	1999-01-10	Nýtt lyfjaform fyrir bóluefni
DK1147117T3 (da)	2004-10-25	Immunologiske adjuvansforbindelser
DE60228758D1 (de)	2008-10-16	Immunisierung gegen chlamydia tracheomatis
WO2003011223A3 (en)	2003-05-01	Immunomodulatory compounds and methods of use thereof
LU91778I2 (fr)	2011-03-14	Menveo - vaccin méningococcique des groupes A,C, W135 et Y conjugué.
ATE463575T1 (de)	2010-04-15	Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
CA2185470A1 (en)	1995-09-21	Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
WO2005105139A3 (en)	2006-04-13	Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy
DE60037900D1 (de)	2008-03-13	Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
DK0939648T3 (da)	2008-02-11	Rotavirusvaccineformuleringer
ATE370745T1 (de)	2007-09-15	Verbesserte polysaccharid- und glykokonjugat- vakzine
DK1140152T3 (da)	2003-12-01	Fremgangsmåde til fremstilling af inaktiverede v/o-emulsion-adjuvans-vacciner
GEP20053446B (en)	2005-02-25	Adjuvant Combination Formulations
WO2002009752A3 (en)	2002-06-27	Immunological adjuvant compounds
WO2000050073A3 (en)	2001-02-22	Caulobacter lps immunoadjuvant
DK0626008T3 (da)	2005-05-02	Vaccine, der som en adjuvans indeholder acemannan
ATE345812T1 (de)	2006-12-15	Antigen-mimotope und vakzine gegen krebserkrankungen
DE69942161D1 (de)	2010-04-29	Genetische Adjuvanz-Impfstoffe